VERVERICA
Ververica, the original creators of Apache Flink and a leader in real-time data streaming, today announced it successfully achieved AICPA Service Organization Control (SOC) 2 Type I certification. This certification, audited by Prescient Assurance, a global leader in security and compliance certifications for B2B/SAAS companies, underscores Ververica’s dedication to implementing robust security measures that protect from evolving cyber threats.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240829939303/en/
Ververica, the original creators of Apache Flink and a leader in real-time data streaming, today announced it successfully achieved AICPA Service Organization Control (SOC) 2 Type I certification. This certification, audited by Prescient Assurance, a global leader in security and compliance certifications for B2B/SAAS companies, underscores Ververica’s dedication to implementing robust security measures that protect from evolving cyber threats. (Graphic: Business Wire)
The SOC 2 Type I certification provides an independent assessment of Ververica’s security, availability, processing integrity, confidentiality, and privacy controls. This accomplishment demonstrates Ververica's adherence to the highest security standards.
“Achieving the SOC 2 Type I attestation is a significant milestone that reflects our unwavering commitment to upholding stringent security standards across all operations,” said Sergei Valukhov, Head of Security and Compliance at Ververica.
“This achievement comes on the heels of our recent ISO 27001 certification, marking yet another important step in our journey to strengthen our security posture. While ISO 27001 focuses on establishing a comprehensive information security management system, SOC 2 Type I specifically attests to our ability to protect sensitive data through robust internal controls and practices,” said Valukhov.
The certification solidifies Ververica’s position as a leader in secure data processing, ensuring that its operations are resilient against emerging cyber threats and providing a secure environment for its customers' critical data.
Ververica's adherence to stringent compliance standards demonstrates its dedication to building and maintaining trust within the market. For more information about Ververica and to view real-time updates on its security protocols, visit the Trust Center: trust.ververica.com.
About Ververica
Ververica, the original creators of Apache Flink®, empowers businesses with high-performance data streaming and processing solutions. Streamlining operations, developer efficiency, and enabling customers to solve real-time use cases reliably and securely. Ververica’s advanced Streaming Data Platform, powered by its cloud native VERA engine, revolutionizes Apache Flink®, making it easy for organizations to harness data insights at scale. With Ververica, customers can meet any business SLA, leveraging advanced data streaming and processing capabilities in real-time or on the lakehouse. Ververica enables businesses to connect, process, govern, and analyze data, across infinite use cases, with flexible deployment options, including public cloud, private cloud, or on-premise environments. Discover more at ververica.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240829939303/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Polpharma Biologics and Libbs Farmacêutica Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases10.12.2025 07:01:00 CET | Press release
Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market. Polpharma Biologics retains full responsibility for the development and manufacturing of the biosimilar. Libbs Farmacêutica will hold an exclusive license for the commercialization, marketing and distribution of the biosimilar in Brazil. This collaboration opens up exciting new opportunities and demonstrates the shared commitment of both companies to delivering innovative and accessible therapies to patients. “Entering the Brazilian market with a biosimilar is a significant step for Polpharma Biologics and reflects our ongoing mission to expand access to high-qual
NayaPay Launches Global QR Payments for Pakistanis via Alipay+10.12.2025 05:00:00 CET | Press release
NayaPay, one of Pakistan’s fastest growing fintech platforms, has launched global QR payments in collaboration with Alipay+, Ant International’s global wallet gateway. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209591389/en/ The partnership enables millions of NayaPay users to scan-and-pay at Alipay+ merchants initially across more than 50 countries, connecting Pakistani consumers to an extensive global ecosystem spanning retail, dining, transport, healthcare, entertainment and more. With this innovative feature, paying abroad just got faster and more affordable. With NayaPay, Pakistanis can now scan and pay securely worldwide with lower costs, less friction, and a seamless checkout experience wherever they go. Alipay+ connects 40 international mobile payment partners to more than 150 million merchants globally. The launch reinforces NayaPay’s commitment to delivering world-class payment experiences to Pakistani consu
Biocytogen Completes STAR Market IPO, Becoming the First “H+A” Global Drug Innovator10.12.2025 03:50:00 CET | Press release
Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (“Biocytogen,” SSE: 688796; HKEX: 02315), a global biotechnology company advancing innovative drug discovery, today announced its successful listing on the Shanghai Stock Exchange STAR Market. This follows the Company’s listing on the Hong Kong Stock Exchange in September 2022 and marks a significant milestone in establishing Biocytogen as the first “H+A” dual-listed global drug innovator, reinforcing its mission to become the global headstream of new drugs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251209977992/en/ The Company’s IPO price was set at 26.68 RMB per share, with an opening price of 58 RMB, representing a 117% increase over the offering price. Based on the opening price, Biocytogen’s market capitalization exceeds 25.9 billion RMB. Biocytogen’s proprietary RenMice® platforms (RenMab™, RenLite®, RenNano®, RenTCR-mimic™) enable the discovery of fully hum
Argo Infrastructure Partners Increases Ownership and Capital Commitment to TierPoint9.12.2025 23:00:00 CET | Press release
The latest investment brings total capital formation under Argo ownership to $3 billionDemonstrates a growing commitment to TierPoint from existing and new capital partners of Argo supporting the continued growth of its leading data center platform Argo Infrastructure Partners, LP (“Argo”), an established mid-market asset manager of essential infrastructure assets in North America, today announced it has acquired on behalf of its managed funds the equity interests of the majority of minority shareholders in TierPoint. The transaction reflects Argo’s continued conviction in TierPoint’s strategy and growth potential during a period of accelerating demand for TierPoint’s enterprise-class data center services. Since Argo’s initial investment in 2020, $3 billion of capital has been raised to fund growth and reduce TierPoint’s cost of capital by terming out debt facilities. The investment capital has advanced TierPoint’s market position as a data center services provider to enterprises, gove
Venture Global Announces Closing of $3,000,000,000 Senior Secured Notes by Venture Global Plaquemines LNG, LLC9.12.2025 22:30:00 CET | Press release
Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Plaquemines LNG, LLC (“VGPL”) has closed an offering of $3,000,000,000 aggregate principal amount of senior secured notes, which has been issued in two series: (i) a series of 6.125% senior secured notes due 2030 in an aggregate principal amount of $1,750,000,000 (the “2030 Notes”) and (ii) a series of 6.500% senior secured notes due 2034 in an aggregate principal amount of $1,250,000,000 (the “2034 Notes” and, together with the 2030 Notes, the “Notes”). The 2030 Notes will mature on December 15, 2030, and the 2034 Notes will mature on June 15, 2034. Venture Global had previously announced the issuance of $2,500,000,000 of senior secured notes by VGPL on April 21, 2025, and $4,000,000,000 of senior secured notes by VGPL on July 3, 2025 (collectively, the “Existing Notes”), bringing the combined aggregate amount of senior secured notes issued by VGPL to $9,500,000,000 since the project
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom